Condition (MeSH)
Diabetes Insipidus, Nephrogenic
ClinicalTrials.gov lists 12 trials for Diabetes Insipidus, Nephrogenic or a narrower condition beneath it. National Center for Research Resources (NCRR) has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
12 of the 12 trials are tagged with Diabetes Insipidus, Nephrogenic itself; the rest are tagged with a narrower condition beneath it.
When did Diabetes Insipidus, Nephrogenic trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2022 | 3 |
| 2021 | 1 |
| 2017 | 1 |
| 2015 | 1 |
| 2009 | 2 |
| 2007 | 1 |
| 1998 | 1 |
| 1995 | 1 |
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 12 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Diabetes Insipidus, Nephrogenic trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Not applicable | 4 |
| Observational | 5 |
How many Diabetes Insipidus, Nephrogenic trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Completed | 7 |
| Terminated | 1 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Diabetes Insipidus, Nephrogenic trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Center for Research Resources (NCRR) | 1 |
Which drugs are being tested for Diabetes Insipidus, Nephrogenic? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| SILDENAFIL | 1 |
| Chlorothiazide | 1 |
| Salmon Calcitonin | 1 |
| ATORVASTATIN | 1 |
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 1% Sevoflurane | 1 |
| hydrochlorothiazide/amiloride | 1 |
| 1% Metformin | 1 |
| Indomethacin SR | 1 |
| PB | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Diabetes Insipidus, Nephrogenic? (20)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A double-blind, randomized, placebo-controlled pilot trial of atorvastatin for nephrogenic diabetes insipidus in lithium users. | Bipolar disorders | 2021 | Yes |
| Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. | Lancet (London, England) | 2019 | Yes |
| Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus: the protocol of a randomized controlled trial. | BMC psychiatry | 2018 | Yes |
| Physiological insights into novel therapies for nephrogenic diabetes insipidus. | American journal of physiology. Renal physiology | 2016 | Yes |
| Efficiency of Osmotic Concentration after Combined Treatment with Vasopressin and Blockage of Prostaglandin Synthesis. | Bulletin of experimental biology and medicine | 2016 | Yes |
Showing 5 of 20 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Arginine vasopressin resistance | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Arginine vasopressin resistance | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Unspecified |
| Arginine vasopressin resistance | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Arginine vasopressin resistance | Prevalence at birth | 1-9 / 1 000 000 | Specific population | Not stated | Exact |
| Arginine vasopressin resistance | Prevalence at birth | 1-9 / 1 000 000 | Specific population | Not stated | Unspecified |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Arginine vasopressin resistance | 223 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Arginine vasopressin resistance | 223 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.